China's National Medical Products Administration has put its reform agenda into print: the document known informally across the industry as the "24 Measures," now the subject of a comparative analysis and interpretation from the CIRS Group, signals how the world's second-largest beauty market intends to police products, ingredients and the companies behind them for the remainder of the decade.

The number matters. Twenty-four discrete regulatory actions, laid out side by side with the rules they amend or supersede, give regulatory affairs teams a checklist rather than a philosophy. CIRS Group's reading of the measures compares the new text against prior requirements clause by clause — the format compliance leads need when they must explain to management exactly which dossiers, labels or safety assessments change and when.

For anyone formulating for the Chinese market, the significance is structural. Since the Cosmetics Supervision and Administration Regulation (CSAR) took effect in 2021, China has moved from a registration-heavy system toward one built on responsibility allocation: the registrant or notifier — not the contract manufacturer — carries the legal weight for product safety and claims. The 24 Measures continue that trajectory. Each clause CIRS highlights in its comparison tightens accountability somewhere in the chain: at the brand owner who files, at the domestic responsible agent who represents foreign entrants, or at the testing house that generates the safety data underpinning a filing.

Foreign brands should read the analysis with procurement and compliance calendars open. Where a measure changes a documentation requirement, the workload lands first on the notified brand and its Chinese responsible agent, who must reconcile the new text with existing dossiers already accepted by the NMPA. Where a measure touches labeling or claims language, the change cascades into artwork, e-commerce listings and in-store materials — a cost line that multiplies across a portfolio.

The comparative format also tells you what did not change, which is often the more useful fact. Measures that restate existing obligations with clarified wording rarely trigger re-filing; measures that alter substantive requirements do. CIRS Group's interpretation distinguishes between the two, and that distinction is what separates a one-line SOP update from a six-month dossier remediation project.

Ingredient suppliers face their own reading. Any measure touching new cosmetic ingredient (NCI) filings affects how quickly a novel raw material can reach Chinese formulators. China's NCI approval pathway — expanded and streamlined under CSAR — remains the gate for differentiation in the market, and each clarification in the 24 Measures shifts the expected timeline and data package for suppliers deciding whether to invest in a China-specific filing. Buyers sourcing for China-bound lines should ask suppliers directly which of the 24 Measures touch their ingredient files and what the answer means for supply continuity.

Contract manufacturers and private-label brands operating in China should map the measures against their quality-management obligations. The reform direction is consistent: heavier consequences for the party that puts the product on the market, sharper inspection powers for regulators, and less tolerance for gaps between what a dossier claims and what a factory does. Companies that treat the 24 Measures as a compliance audit checklist — rather than waiting for enforcement actions to define the priorities — will spend less retroactively.

Salon and treatment-channel professionals feel these changes indirectly but concretely. Regulatory tightening on claims and safety data eventually reshapes which professional-use products clear the Chinese market and how quickly new treatment protocols can be supported with compliant marketing language.

The practical next step is unglamorous: regulatory teams should translate CIRS Group's comparative analysis into an internal gap assessment, measure by measure, with an owner and a deadline attached to each of the 24 items. Watch for the NMPA's implementing notices and transition periods that follow — those dates, not the headline document, will determine filing calendars through the next 18 to 24 months.